161 related articles for article (PubMed ID: 34131576)
1. Chemotherapy-Induced Nausea and Vomiting (CINV) with GI Cancer Chemotherapy: Do We Need CINV Risk Score Over and Above Antiemetic Guidelines in Prescribing Antiemetic Regime?
D'Souza A; Pawar D; Ramaswamy A; Turkar S; Bhargava P; Kapoor A; Mandavkar S; Nashikkar C; Ostwal V
South Asian J Cancer; 2020 Oct; 9(4):240-244. PubMed ID: 34131576
[No Abstract] [Full Text] [Related]
2. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
3. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
4. [Assessment of chemotherapy-induced nausea and vomiting(CINV)using MASCC antiemesis tool].
Yamaguchi M; Ogawa T; Watanabe M; Anami S; Kamigaki S; Nishikawa N; Ono T; Furukawa H
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1691-6. PubMed ID: 19838029
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
[TBL] [Abstract][Full Text] [Related]
6. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
8. Effect of Persian Medicine Remedy on Chemotherapy Induced Nausea and Vomiting in Breast Cancer: A Double Blind, Randomized, Crossover Clinical Trial.
Nazari M; Taghizadeh A; Bazzaz MM; Rakhshandeh H; Shokri S
Electron Physician; 2017 Jan; 9(1):3535-3543. PubMed ID: 28243404
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study.
Patel P; Lavoratore SR; Flank J; Kemp M; Vennettilli A; Vol H; Taylor T; Zelunka E; Maloney AM; Nathan PC; Dupuis LL
Support Care Cancer; 2020 Feb; 28(2):933-938. PubMed ID: 31177392
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients: A Multicenter Prospective Observational Study.
Huang X; Li X; Li J; Luo L; Chen H; Tan Y; Wei T; Li X; Guo L; Cheng J
Asia Pac J Oncol Nurs; 2021; 8(4):433-437. PubMed ID: 34159237
[TBL] [Abstract][Full Text] [Related]
11. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D
Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians.
Parathoduvil AA; Sisupalan A; Rema PL
J Clin Diagn Res; 2017 May; 11(5):FC10-FC14. PubMed ID: 28658796
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
17. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
[TBL] [Abstract][Full Text] [Related]
18. Control of chemotherapy-induced nausea and vomiting in patients with gastrointestinal tumours.
Barle R; Vovk T; Štabuc B; Verbič MD
Eur J Hosp Pharm; 2017 Mar; 24(2):80-84. PubMed ID: 31156909
[TBL] [Abstract][Full Text] [Related]
19. Effects of auricular acupressure on chemotherapy-induced nausea and vomiting in breast cancer patients: a preliminary randomized controlled trial.
Tan JY; Molassiotis A; Suen LKP; Liu J; Wang T; Huang HR
BMC Complement Med Ther; 2022 Mar; 22(1):87. PubMed ID: 35331208
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
